Although Vanda Pharmaceuticals VNDA and partner Novartis NVS recently launched their antipsychotic Fanapt in the United States, we're keeping our fair value estimate intact until we begin to see meaningful sales data and can better estimate the drug's commercial performance. Furthermore, with royalty rates yet to be disclosed, there remains much uncertainty around how sales will translate to Vanda's top line. The firm is working toward approval in other countries as well, and we expect Vanda to strike a similar deal with Novartis for commercialization rights outside North America following Fanapt's marketing approval abroad. 
Share:  Although Vanda Pharmaceuticals VNDA and partner Novartis <span class="company">NVS</span> recently launched their antipsychotic Fanapt in the United States, we're keeping our fair value estimate intact until we begin to see meaningful sales data and can better estimate the drug's commercial performance. Furthermore, with royalty rates yet to be disclosed, there remains much uncertainty around how sales will translate to Vanda's top line. The firm is working toward approval in other countries as well, and we expect Vanda to strike a similar deal with Novartis for commercialization rights outside North America following Fanapt's marketing approval abroad. Tweet this 

Analysts at Credit Suisse have said a takeover would move Teva's global generics market share to around 19 percent, widening the gap over No 2, Novartis's Sandoz unit, at about 11 percent. 
Share:  <span class="sent">Analysts at <span class="analyst">Credit Suisse</span> have said a takeover would move Teva's global generics market share to around 19 percent, widening the gap over No 2, <span class="company">Novartis</span>'s Sandoz unit, at about 11 percent.</span> Tweet this 

"Given Novartis' decision not to pursue development in the US, the market will assume that the probability of a successful registration of a generic product in the US has reduced," added Savvas Neophytou of Panmure Gordon. 
Share:  <span class="sent">"Given <span class="company">Novartis</span>' decision not to pursue development in the US, the market will assume that the probability of a successful registration of a generic product in the US has reduced," added <span class="analyst">Savvas Neophytou</span> of Panmure Gordon.</span> Tweet this 

"The market has seen this as Novartis dumping the product and increased risk for Vectura," said Keith Redpath, analyst at FinnCap. 
Share:  <span class="sent">"The market has seen this as <span class="company">Novartis</span> dumping the product and increased risk for Vectura," said <span class="analyst">Keith Redpath</span>, analyst at FinnCap.</span> Tweet this 

Novartis's partner Vectura Group Plc took full control of the U. S development and commercialization of the drug, known as VR315, a potential generic version to Glaxo's Advair asthma treatment. "Given Novartis's decision not to pursue development in the U. S., the market will assume that the probability of a successful registration of a generic product in the U. S has reduced," wrote Savvas Neophytou , an analyst at Panmure Gordon & Co in a report today. 
Share:  <span class="company">Novartis</span>'s partner Vectura Group Plc took full control of the U. S development and commercialization of the drug, known as VR315, a potential generic version to Glaxo's Advair asthma treatment.<span class="sent"> "Given <span class="company">Novartis</span>'s decision not to pursue development in the U. S., the market will assume that the probability of a successful registration of a generic product in the U. S has reduced," wrote <span class="analyst">Savvas Neophytou</span> , an analyst at Panmure Gordon & Co in a report today.</span> Tweet this 

Analyst Savvas Neophytou at Panmure Gordon said:Given Novartis' decision not to pursue development in the US, the market will assume that the probability of a successful registration of a generic product in the US has reduced. 
Share:  <span class="sent">Analyst <span class="analyst">Savvas Neophytou</span> at Panmure Gordon said:Given <span class="company">Novartis</span>' decision not to pursue development in the US, the market will assume that the probability of a successful registration of a generic product in the US has reduced.</span> Tweet this 

Not only is Vectura is smaller company with limited development expertise of US generics but its balance sheet is also limited which may define the amount of risk it is willing to take.Evolution Securities analyst Dominic Valder added:[The move] implies that the generic Advair opportunity in the US was going to be smaller and more deferred than [Novartis] hoped and therefore they chose to return the right to Vectura. 
Share:  <span class="sent">Not only is Vectura is smaller company with limited development expertise of US generics but its balance sheet is also limited which may define the amount of risk it is willing to take.Evolution Securities analyst <span class="analyst">Dominic Valder</span> added:[The move] implies that the generic Advair opportunity in the US was going to be smaller and more deferred than [<span class="company">Novartis</span>] hoped and therefore they chose to return the right to Vectura.</span> Tweet this 

The folks at GlaxoSmithKline must be celebrating today: Rival Novartis has handed back U.S. rights to a drug that might have become a copycat version of the GSK blockbuster Advair. That move gives Glaxo one less problem to worry about. . GSK chief Andrew Witty has been pooh poohing the potential of generic rivals to that best selling lung drug, which accounted for $7.6 billion in 2009 sales. 
Share:  The folks at GlaxoSmithKline must be celebrating today: Rival <span class="company">Novartis</span> has handed back U.S. rights to a drug that might have become a copycat version of the GSK blockbuster Advair. That move gives Glaxo one less problem to worry about. . GSK chief Andrew Witty has been pooh poohing the potential of generic rivals to that best selling lung drug, which accounted for $7.6 billion in 2009 sales. Tweet this 

Novartis's partner Vectura Group Plc took full control of the U. S development and commercialization of the drug, known as VR315, a potential generic version to Glaxo's Advair asthma treatment. "Given Novartis's decision not to pursue development in the U. S., the market will assume that the probability of a successful registration of a generic product in the U. S has reduced," wrote Savvas Neophytou, an analyst at Panmure Gordon & Co in a report today. 
Share:  <span class="company">Novartis</span>'s partner Vectura Group Plc took full control of the U. S development and commercialization of the drug, known as VR315, a potential generic version to Glaxo's Advair asthma treatment.<span class="sent"> "Given <span class="company">Novartis</span>'s decision not to pursue development in the U. S., the market will assume that the probability of a successful registration of a generic product in the U. S has reduced," wrote <span class="analyst">Savvas Neophytou</span>, an analyst at Panmure Gordon & Co in a report today.</span> Tweet this 

Analysts at Credit Suisse have said a takeover would move Teva's global generics market share to around 19 percent, widening the gap over No. 2, Novartis's Sandoz unit, at about 11 percent. 
Share:  <span class="sent">Analysts at <span class="analyst">Credit Suisse</span> have said a takeover would move Teva's global generics market share to around 19 percent, widening the gap over No. 2, <span class="company">Novartis</span>'s Sandoz unit, at about 11 percent.</span> Tweet this